****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 13](#_Toc73955677)

[1.1 Statement of the Report 13](#_Toc73955678)

[1.2 Executive Summary 15](#_Toc73955679)

[2. INTRODUCTION 17](#_Toc73955680)

[2.1 Discovery of iPSCs 18](#_Toc73955681)

[2.2 Barriers in iPSC Application 19](#_Toc73955682)

[2.3 Timeline and Cost of iPSC Development 19](#_Toc73955683)

[2.4 Current Status of iPSCs Industry 20](#_Toc73955684)

[2.4.1 Share of iPSC-based Research within the Overall Stem Cell Industry 20](#_Toc73955685)

[2.4.2 Major Focuses of iPSC Companies 21](#_Toc73955686)

[2.4.3 Commercially Available iPSC-Derived Cell Types 21](#_Toc73955687)

[2.4.4 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays 23](#_Toc73955688)

[2.4.5 Toxicology/Safety Testing Assays using iPSC-Derived Cell Types 23](#_Toc73955689)

[2.5 Currently Available iPSC Technologies 25](#_Toc73955690)

[2.6 Advantages and Limitations of iPSCs Technology 27](#_Toc73955691)

[3. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (iPSCs) 28](#_Toc73955692)

[3.1 First iPSC generation from Mouse Fibroblasts, 2006 28](#_Toc73955693)

[3.2 First Human iPSC Generation, 2007 29](#_Toc73955694)

[3.3 Creation of CiRA, 2010 29](#_Toc73955695)

[3.4 First High-Throughput Screening Using iPSCs, 2012 30](#_Toc73955696)

[3.5 First iPSC Clinical Trial Approved in Japan, 2013 30](#_Toc73955697)

[3.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 2014 30](#_Toc73955698)

[3.7 EBiSC Founded, 2014 30](#_Toc73955699)

[3.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017 31](#_Toc73955700)

[3.9 Clinical Trials for Parkinson’s disease using Allogeneic iPSCs, 2018 31](#_Toc73955701)

[3.10 Commercial iPSC Plant SMaRT Established, 2018 31](#_Toc73955702)

[3.11 First iPSC Therapy Center in Japan, 2019 31](#_Toc73955703)

[3.12 The First U.S.-based NIH Sponsored Clinical Trial using iPSCs, 2019 32](#_Toc73955704)

[3.13 Cynata Therapeutics’ Worlds Largest Phase III Clinical Trial, 2020 32](#_Toc73955705)

[4. RESEARCH PUBLICATIONS ON iPSCs 33](#_Toc73955706)

[4.1 Categories of Research Publications 34](#_Toc73955707)

[4.2 Percent Share of Published Articles by Disease Type 35](#_Toc73955708)

[4.3 Number of Articles by Country 36](#_Toc73955709)

[5. iPSCs: PATENT LANDSCAPE 38](#_Toc73955710)

[5.1 Timeline and Status of Patents 38](#_Toc73955711)

[5.2 Patent Filing Destinations 39](#_Toc73955712)

[5.2.1 Patent Applicant’s Origin 40](#_Toc73955713)

[5.2.2 Top Ten Global Patent Applicants 41](#_Toc73955714)

[5.2.3 Collaborating Applicants of Patents 42](#_Toc73955715)

[5.3 Patent Application Trends iPSC Preparation Technologies 43](#_Toc73955716)

[5.4 Patent Application Trends in iPSC Differentiation Technologies 46](#_Toc73955717)

[5.5 Patent Application Trends in Disease-Specific Cell Technologies 47](#_Toc73955718)

[6. CLINICAL TRIALS INVOLVING iPSCs 50](#_Toc73955719)

[6.1 Current Clinical Trials Landscape 51](#_Toc73955720)

[6.1.1 Clinical Trials Involving iPSCs by Major Diseases 58](#_Toc73955721)

[6.1.2 Clinical Trials Involving iPSCs by Country 58](#_Toc73955722)

[7. FUNDING FOR iPSCs 60](#_Toc73955723)

[7.1 Value of NIH Funding for iPSCs 61](#_Toc73955724)

[7.1.1 NIH’s Intended Funding Through its Component Organizations in 2020 64](#_Toc73955725)

[7.1.2 NIH Funding for Select Universities for iPSC Studies 65](#_Toc73955726)

[7.2 CIRM Funding for iPSCs 67](#_Toc73955727)

[8. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW 69](#_Toc73955728)

[8.1 Reprogramming Factors 71](#_Toc73955729)

[8.1.1 Pluripotency-Associated Transcription Factors 71](#_Toc73955730)

[8.1.2 Different Cell Sources and Different Combinations of Factors 73](#_Toc73955731)

[8.1.3 Delivery of Reprogramming Factors 73](#_Toc73955732)

[8.1.4 Integrative Delivery Systems 74](#_Toc73955733)

[8.1.4.1 Integrative Viral Vectors 74](#_Toc73955734)

[8.1.4.2 Integrative Non-Viral Vectors 75](#_Toc73955735)

[8.1.5 Non-Integrative Delivery Systems 75](#_Toc73955736)

[8.1.5.1 Non-Integrative Viral Vectors 75](#_Toc73955737)

[8.1.5.2 Non-Integrative Non-Viral Delivery 75](#_Toc73955738)

[8.2 Overview of Four Key Methods of Gene Delivery 75](#_Toc73955739)

[8.3 Comparative Effectiveness of Different Vector Types 76](#_Toc73955740)

[8.4 Genome Editing Technologies in iPSCs Generation 77](#_Toc73955741)

[9. HUMAN iPSC BANKING 80](#_Toc73955742)

[9.1 Cell Sources for iPSCs Banking 81](#_Toc73955743)

[9.2 Reprogramming methods used in iPSC Banking 81](#_Toc73955744)

[9.2.1 Factors used in reprogramming by Different Banks 81](#_Toc73955745)

[9.3 Workflow in iPSC Banks 82](#_Toc73955746)

[9.4 Existing iPSC Banks 83](#_Toc73955747)

[9.4.1 California Institute for Regenerative Medicine (CIRM) 83](#_Toc73955748)

[9.4.1.1 CIRM iPSC Repository 84](#_Toc73955749)

[9.4.1.2 Key Partnerships Supporting CIRM’s iPSC Repository 85](#_Toc73955750)

[9.4.2 Regenerative Medicine Program (RMP) 85](#_Toc73955751)

[9.4.2.1 Research Grade iPSC Lines for Orphan and Rare Diseases from RMP 86](#_Toc73955752)

[9.4.2.2 RMP’s Stem Cell Translation Laboratory (SCTL) 88](#_Toc73955753)

[9.4.3 Center for iPS Cell Research and Application (CiRA) 88](#_Toc73955754)

[9.4.3.1 FiT: Facility for iPS Cell Therapy 88](#_Toc73955755)

[9.4.4 European Bank for Induced Pluripotent Stem Cells (EBiPC) 89](#_Toc73955756)

[9.4.5 Korean Society for Cell Biology (KSCB) 90](#_Toc73955757)

[9.4.6 Human Induced Pluripotent Stem Cell Intitiative (HipSci) 90](#_Toc73955758)

[9.4.7 RIKEN – BioResource Research Center (BRC) 90](#_Toc73955759)

[9.4.8 Taiwan Human Disease iPSC Consortium 92](#_Toc73955760)

[9.4.9 WiCell 93](#_Toc73955761)

[10. BIOMEDICAL APPLICATIONS OF iPSCs 94](#_Toc73955762)

[10.1 iPSCs in Basic Research 95](#_Toc73955763)

[10.1.1 Understanding Cell Fate Control 95](#_Toc73955764)

[10.1.2 Cell Rejuvenation 95](#_Toc73955765)

[10.1.3 Studying Pluripotency 95](#_Toc73955766)

[10.1.4 Tissue and Organ Development and Physiology 96](#_Toc73955767)

[10.1.5 Generation of Human Gametes from iPSCs 96](#_Toc73955768)

[10.1.6 Providers of iPSC-Related Services for Researchers 96](#_Toc73955769)

[10.2 iPSCs in Drug Discovery 98](#_Toc73955770)

[10.2.1 Drug Discovery for Cardiovascular Disease using iPSCs 99](#_Toc73955771)

[10.2.2 Drug Discovery for Neurological and Neuropsychiatric Diseases 100](#_Toc73955772)

[10.2.3 Drug Discovery for Rare Diseases using iPSCs 102](#_Toc73955773)

[10.3 iPSCs in Toxicology Studies 104](#_Toc73955774)

[10.3.1 Relative Use of iPSC-Derived Cell Types within Toxicity Testing 106](#_Toc73955775)

[10.4 iPSCs in Disease Modeling 107](#_Toc73955776)

[10.4.1 Cardiovascular Diseases Modeled with iPSCs 112](#_Toc73955777)

[10.4.2 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling 113](#_Toc73955778)

[10.4.3 Proportion of iPSC Sources in Cardiac Studies 114](#_Toc73955779)

[10.4.4 Proportion of Vector Types used in Reprogramming 115](#_Toc73955780)

[10.4.5 Proportion of Differentiated Cardiomyocytes used in Disease Modeling 116](#_Toc73955781)

[10.4.6 iPSC-Derived Organoids for Modeling Development and Disease 117](#_Toc73955782)

[10.4.7 Modeling Liver Diseases using iPSC-derived Hepatocytes 118](#_Toc73955783)

[10.4.8 iPSCs in Neurodegenerative Disease Modeling 120](#_Toc73955784)

[10.4.9 Cancer-Derived iPSCs 125](#_Toc73955785)

[10.5 iPSCs within Cell-Based Therapies 126](#_Toc73955786)

[10.5.1 iPSC-Derived Therapeutics under Development Worldwide 127](#_Toc73955787)

[10.5.1.1 Clinical Trials for AMD 129](#_Toc73955788)

[10.5.1.2 Autologous iPSC-RPE for AMD 130](#_Toc73955789)

[10.5.1.3 Allogeneic iPSC-RPE for AMD 130](#_Toc73955790)

[10.5.1.4 iPSC-Derived Dopaminergic Neurons for Parkinson’s disease 130](#_Toc73955791)

[10.5.1.5 iPSC-Derived NK Cells for Solid Cancers 131](#_Toc73955792)

[10.5.1.6 iPSC-derived Cells for GvHD 131](#_Toc73955793)

[10.5.1.7 iPSC-derived Cells for Spinal Cord Injury 131](#_Toc73955794)

[10.5.1.8 iPSC-derived Cardiomyocytes for Ischemic Cardiomyopathy 131](#_Toc73955795)

[10.5.1.9 Cynata’s CYP-001 for Acute Respiratory Distress Syndrome (ARDS) 132](#_Toc73955796)

[10.5.1.10 Cynata’s CYP-004 for Osteoarthritis 132](#_Toc73955797)

[10.5.1.11 Cynata’s CYP-002 for Critical Limb Ischemia (CLI) 132](#_Toc73955798)

[10.5.1.12 iPSC-Derived RPE Cells for Age-Related Macular Degeneration 132](#_Toc73955799)

[10.5.1.13 Stem Cell Treatment for Aplastic Anemia 133](#_Toc73955800)

[10.5.1 All Known Companies Developing iPSC-Derived Cell Therapeutics Worldwide 133](#_Toc73955801)

[10.5.2 U.S. Clinical Trials Involving iPSCs 135](#_Toc73955802)

[11. OTHER NOVEL APPLICATIONS OF iPSCs 137](#_Toc73955804)

[11.1 iPSCs in Tissue Engineering 137](#_Toc73955805)

[11.1.1 3D Bioprinting Techniques 137](#_Toc73955806)

[11.1.2 Biomaterials 138](#_Toc73955807)

[11.1.3 3D Bioprinting Strategies 138](#_Toc73955808)

[11.1.4 Bioprinting Undifferentiated iPSCs 138](#_Toc73955809)

[11.1.5 Bioprinting iPSC-Differentiated Cells 139](#_Toc73955810)

[11.2 iPSCs in Animal Conservation 142](#_Toc73955811)

[11.2.1 iPSC Lines for the Preservation of Endangered Species of Animals 142](#_Toc73955812)

[11.2.2 iPSCs in Wildlife Conservation 143](#_Toc73955813)

[11.3 iPSCs and Cultured Meat 145](#_Toc73955814)

[11.3.1 Funding Raised by Cultured Meat Companies 146](#_Toc73955815)

[11.3.4 Global Market for Cultured Meat 147](#_Toc73955816)

[12. DEAL-MAKING WITHIN THE iPSC SECTOR 149](#_Toc73955817)

[12.1 Novo Nordisk’s Deal with Heartseed 149](#_Toc73955818)

[12.2 Partnership between Neuropath Biotechnology Ltd. and Hopstem Biotechnology 149](#_Toc73955819)

[12.3 License Agreement between FUJIFILM Cellular Dynamics and Sana Biotechnology 150](#_Toc73955820)

[12.4 Century Therapeutics Closes $160 Million Series C Financing 150](#_Toc73955821)

[12.5 Bluerock Gains Access to Ncardia’s iPSCs-derived Cardiomyocytes 150](#_Toc73955822)

[12.6 Fate Therapeutics’ deal with Janssen Biotech 151](#_Toc73955823)

[12.7 Century Therapeutics Acquires Empirica Therapeutics 151](#_Toc73955824)

[12.8 $250 million Raised by Century Therapeutics 151](#_Toc73955825)

[12.9 BlueRock Therapeutics Launched with $225 Million 151](#_Toc73955826)

[12.10 Collaboration between Allogene Therapeutics and Notch Therapeutics 152](#_Toc73955827)

[12.11 Acquisition of Semma Therapeutics by Vertex Therapeutics 152](#_Toc73955828)

[12.12 Evotec’s Extended Collaboration with BMS 152](#_Toc73955829)

[12.13 Licensing Agreement between Allele Biotechnology and Astellas Pharma 153](#_Toc73955830)

[12.14 Codevelopment Agreement between Allele & SCM Lifesciences 153](#_Toc73955831)

[12.15 Fate Therapeutics Signs $100 Million Deal with Janssen 153](#_Toc73955832)

[12.16 Allele’s Deal with Alpine Biotherapeutics 153](#_Toc73955833)

[12.17 Editas and BlueRock’s Development Agreement 154](#_Toc73955834)

[12.18 Avery Therapeutics and I Peace, Inc. Sign Service Agreement 154](#_Toc73955835)

[12.19 Evotec SE Signed a Licensing and Investment Agreement with panCELLa, Inc. 154](#_Toc73955836)

[13. MARKET OVERVIEW 155](#_Toc73955837)

[13.1 Global Market for iPSCs by Geography 157](#_Toc73955838)

[13.2 Global Market for iPSCs by Technology 158](#_Toc73955839)

[13.3 Global Market for iPSCs by Biomedical Application 160](#_Toc73955840)

[13.4 Global Market for iPSCs by Cell Types 162](#_Toc73955841)

[3.5 Market Drivers 164](#_Toc73955842)

[13.6 Market Restraints 164](#_Toc73955843)

[13.6.1 Economic Issues 164](#_Toc73955845)

[13.6.2 Genomic Instability 165](#_Toc73955846)

[13.6.3 Immunogenicity 165](#_Toc73955847)

[13.6.4 Biobanking of iPSCs 165](#_Toc73955848)

[14. COMPANY PROFILES 166](#_Toc73955849)

[14.1 Addgene, Inc. 166](#_Toc73955850)

[14.1.1 Viral Plasmids 166](#_Toc73955851)

[14.2 Aleph Farms 167](#_Toc73955852)

[14.3 Allele Biotechnology and Pharmaceuticals, Inc. 168](#_Toc73955853)

[14.3.1 iPSC Reprogramming and Differentiation 168](#_Toc73955854)

[14.4 AMS Biotechnology Europe, Ltd. (AMSBIO) 169](#_Toc73955855)

[14.4.1 Services 169](#_Toc73955856)

[14.4.2 Products 169](#_Toc73955857)

[14.4.3 Corneal Epithelial Cells Cultured in StemFit in Clinical Trials 171](#_Toc73955858)

[14.5 ALSTEM, INC. 172](#_Toc73955859)

[14.5.1 Products 172](#_Toc73955860)

[14.5.2 Services 172](#_Toc73955861)

[14.6 Applied Biological Materials, Inc. (ABM) 173](#_Toc73955862)

[14.6.1 Gene Expression Vectors and Viruses 173](#_Toc73955863)

[14.7 Applied StemCell, Inc. 174](#_Toc73955864)

[14.7.1 Services & Products 174](#_Toc73955865)

[14.8 American Type Culture Collection (ATCC) 175](#_Toc73955866)

[14.8.1 Product 175](#_Toc73955867)

[14.9 Applied StemCell (ASC), Inc. 176](#_Toc73955868)

[14.9.1 Products 176](#_Toc73955869)

[14.10 Aruna Bio, Inc. 177](#_Toc73955870)

[14.10.1 Program in Stroke 177](#_Toc73955871)

[14.10.2 Exosomes as Therapeurics 177](#_Toc73955872)

[14.11 Aspen Neuroscience, Inc. 178](#_Toc73955873)

[14.11.1 Technology 178](#_Toc73955874)

[14.12 Avery Therapeutics 179](#_Toc73955875)

[14.12.1 MyCardia 179](#_Toc73955876)

[14.13 Axol Bioscience, Ltd. 180](#_Toc73955877)

[14.13.1 iPSC-derived Cells 180](#_Toc73955878)

[14.13.2 Disease Models 180](#_Toc73955879)

[14.13.3 Primary Cells 181](#_Toc73955880)

[14.13.4 Media & Reagents 181](#_Toc73955881)

[14.13.5 Services 181](#_Toc73955882)

[14.14 Beckman Coulter Life Sciences 182](#_Toc73955883)

[14.14.1 Cell Counters, Sizers and Media Analyzers 182](#_Toc73955884)

[14.15 BD Biosciences 183](#_Toc73955885)

[14.15.1 Products 183](#_Toc73955886)

[14.16 BioCat GmbH 184](#_Toc73955887)

[14.16.1 Products & Services 184](#_Toc73955888)

[14.17 BlueRock Therapeutics 185](#_Toc73955889)

[14.17.1 CELL + GENE Platform 185](#_Toc73955890)

[14.18 BrainXell 186](#_Toc73955891)

[14.18.1 Products 186](#_Toc73955892)

[14.19 Cellaria 187](#_Toc73955893)

[14.19.1 Product 187](#_Toc73955894)

[14.20 Cell Biolabs, Inc. 188](#_Toc73955895)

[14.20.1 Products 188](#_Toc73955896)

[14.21 CellGenix GmbH 189](#_Toc73955897)

[14.21.1 Products 189](#_Toc73955898)

[14.22 Cell Signaling Technology 190](#_Toc73955899)

[14.22.1 Products 190](#_Toc73955900)

[14.23 Cellular Engineering Technologies (CET) 191](#_Toc73955901)

[14.23.1 iPS Cell Lines 191](#_Toc73955902)

[14.24 Cellular Dynamics International, Inc. 192](#_Toc73955903)

[14.24.1 Products 192](#_Toc73955904)

[14.25 Censo Biotechnologies, Ltd. 194](#_Toc73955905)

[14.25.1 Human iPSC Reprogramming Services 194](#_Toc73955906)

[14.25.2 iPSC Gene Editing Services 194](#_Toc73955907)

[14.25.3 iPSC Target Validation and Assay Services 194](#_Toc73955908)

[14.26 Century Therapeutics, LLC 195](#_Toc73955909)

[14.26.1 Allogeneic Immune Cell Therapy 195](#_Toc73955910)

[14.27 CiRA 196](#_Toc73955911)

[14.27.1 Collaborations 196](#_Toc73955912)

[14.28 Corning, Inc. 197](#_Toc73955913)

[14.28.1 Products 197](#_Toc73955914)

[14.29 Creative Bioarray 199](#_Toc73955915)

[14.29.1 Products 199](#_Toc73955916)

[14.30 Cynata Therapeutics Ltd. 201](#_Toc73955917)

[14.30.1 Cymerus MSCs 201](#_Toc73955918)

[14.30.2 Cynata’s Lead in iPSC-based Clinical Trials 201](#_Toc73955919)

[14.30.2.1 CYP-001 202](#_Toc73955920)

[14.30.2.2 CYP-002 202](#_Toc73955921)

[14.30.2.3 CYP-004 203](#_Toc73955922)

[14.30.2.4 MEND Clinical Trial 203](#_Toc73955923)

[14.31 Cytovia Therapeutics 204](#_Toc73955924)

[14.31.1 iPSC CAR NK Cells 204](#_Toc73955925)

[14.32 DefiniGEN 205](#_Toc73955926)

[14.32.1 OptiDIFF iPSC Platform 205](#_Toc73955927)

[14.32.2 Service 205](#_Toc73955928)

[14.32.3 Patient-Derived Custom Cell Lines 205](#_Toc73955929)

[14.32.4 Hepatocytes WT 206](#_Toc73955930)

[14.32.5 Hepatocyte A1ATD 206](#_Toc73955931)

[14.32.6 Hepatocyte GSD1a 206](#_Toc73955932)

[14.32.7 Hepatocyte NAFLD 206](#_Toc73955933)

[14.32.8 Hepatocyte FH 207](#_Toc73955934)

[14.32.9 Pancreatic WT 207](#_Toc73955935)

[14.32.10 Pancreatic MODY3 207](#_Toc73955936)

[14.33 Evotec A.G. 208](#_Toc73955937)

[14.33.1 iPSC-Based Drug Discovery Platform 208](#_Toc73955938)

[14.34 Fate Therapeutics, Inc. 209](#_Toc73955939)

[14.34.1 iPSC Platform 209](#_Toc73955940)

[14.34.2 Collaboration with ONO Pharmaceutical Co., Ltd. 209](#_Toc73955941)

[14.34.3 Collaboration with Memorial Sloan-Kettering Cancer Center 210](#_Toc73955942)

[14.34.4 Collaboration with University of California, San Diego 210](#_Toc73955943)

[14.34.5 Collaboration with Oslo University Hospital 210](#_Toc73955944)

[14.35 FUJIFILM Cellular Dynamics, Inc. 211](#_Toc73955945)

[14.35.1 iCell Products 211](#_Toc73955946)

[14.35.2 MyCell Products 211](#_Toc73955947)

[14.35.3 FCDI’s Partners & Providers 211](#_Toc73955948)

[14.35.4 Groundbreaking Cellular Therapy Applications 213](#_Toc73955949)

[14.35.5 New Paradigm for Drug Discovery 213](#_Toc73955950)

[14.35.6 FCDI & Stem Cell Banking 214](#_Toc73955951)

[14.36 GeneCopoeia, Inc. 215](#_Toc73955952)

[14.36.1 Products & Services 215](#_Toc73955953)

[14.37 GenTarget, Inc. 217](#_Toc73955954)

[14.37.1 Products 217](#_Toc73955955)

[14.37.2 Services 217](#_Toc73955956)

[14.38 Healios KK 218](#_Toc73955957)

[14.38.1 Healios’ iPSCs for Regenerative Medicine 218](#_Toc73955958)

[14.39 Heartseed, Inc. 219](#_Toc73955959)

[14.39.1 Technology 219](#_Toc73955960)

[14.40 Hopstem Biotechnology LLC 220](#_Toc73955961)

[14.40.1 Products & Services 220](#_Toc73955962)

[14.41 InvivoGen 221](#_Toc73955963)

[14.41.1 Products 221](#_Toc73955964)

[14.42 iPS Portal, Inc. 222](#_Toc73955965)

[14.42.1 Services 222](#_Toc73955966)

[14.43 I Peace, Inc. 223](#_Toc73955967)

[14.43.1 Mass Production of iPSCs 223](#_Toc73955968)

[14.44 iXCells Biotechnologies 224](#_Toc73955969)

[14.44.1 Products 224](#_Toc73955970)

[14.45 Lonza Group, Ltd. 225](#_Toc73955971)

[14.45.1 Nucleofector Technology 225](#_Toc73955972)

[14.46 Merck/Sigma Aldrich 226](#_Toc73955973)

[14.46.1 Products 226](#_Toc73955974)

[14.47 Megakaryon Corporation 227](#_Toc73955975)

[14.47.1 Technology 227](#_Toc73955976)

[14.48 Metrion Biosciences, Ltd. 228](#_Toc73955977)

[14.48.1 Cardiac Translational Assays 228](#_Toc73955978)

[14.49 Miltenyi Biotec B.V. & Co. KG 229](#_Toc73955979)

[14.49.1 Cell Manufacturing Platform 229](#_Toc73955980)

[14.50 Rue Adrienne Bolland 230](#_Toc73955981)

[14.50.1 iPSC Solutions for Cell Therapy 230](#_Toc73955982)

[14.50.2 Drug Safety and Toxicity Services 230](#_Toc73955983)

[14.51 NeuCyte 231](#_Toc73955984)

[14.51.1 Technology 231](#_Toc73955985)

[14.52 Newcells Biotech 232](#_Toc73955986)

[14.52.1 Expertise 232](#_Toc73955987)

[14.52.2 iPSC Reprogramming Services 232](#_Toc73955988)

[14.52.3 Assay Products and Services 232](#_Toc73955989)

[14.52.4 Assay Development 233](#_Toc73955990)

[14.53 Novo Nordisk A/S 233](#_Toc73955991)

[14.53.1 Partnership with HeartSeed 233](#_Toc73955992)

[14.54 PeproTech 234](#_Toc73955993)

[14.54.1 Products 234](#_Toc73955994)

[14.55 Phenocell SAS 235](#_Toc73955995)

[14.55.1 Human iPSCs 235](#_Toc73955996)

[14.56 Platelet BioGenesis 236](#_Toc73955997)

[14.56.1 Technology 236](#_Toc73955998)

[14.57 Pluricell Biotech 237](#_Toc73955999)

[14.57.1 Pluricell’s Projects 237](#_Toc73956000)

[14.58 PromoCell GmbH 238](#_Toc73956001)

[14.58.1 Products 238](#_Toc73956002)

[14.59 Qiagen 239](#_Toc73956003)

[14.59.1 Single Cell Analysis 239](#_Toc73956004)

[14.60 R&D Systems, Inc. 240](#_Toc73956005)

[14.60.1 Products 240](#_Toc73956006)

[14.61 ReproCELL 241](#_Toc73956007)

[14.61.1 Services 241](#_Toc73956008)

[14.61.2 Products 241](#_Toc73956009)

[14.62 RHEINCELL Therapeutics GmbH 242](#_Toc73956010)

[14.62.1 GMP-Grade iPSC Products 242](#_Toc73956011)

[14.62.2 Services 242](#_Toc73956012)

[14.63 Stemson Therapeutics 243](#_Toc73956013)

[14.63.1 Hair Follicle Biology 243](#_Toc73956014)

[14.64 TEMCELL Technologies 244](#_Toc73956015)

[14.64.1 Products 244](#_Toc73956016)

[14.65 Stemina Biomarker Discovery 245](#_Toc73956017)

[14.65.1 Cardio quickPredict 245](#_Toc73956018)

[14.65.2 devTOX quickPredict 245](#_Toc73956019)

[14.66 Synthego Corp. 246](#_Toc73956020)

[14.66.1 CRISPR-Edited iPSCs 246](#_Toc73956021)

[14.67 System Biosciences (SBI) 247](#_Toc73956022)

[14.67.1 Products 247](#_Toc73956023)

[14.68 Takara Bio 248](#_Toc73956024)

[14.68.1 Stem Cell Research Products 248](#_Toc73956025)

[14.69 Takeda Pharmaceutical Co., Ltd. 249](#_Toc73956026)

[14.69.1 Collaboration between CiRA and Takeda 249](#_Toc73956027)

[14.69.2 FUJIFILM’s Collaboration with Takeda 249](#_Toc73956028)

[14.70 Tempo Bioscience 250](#_Toc73956029)

[14.70.1 Human Cell Models 250](#_Toc73956030)

[ Tempo-iSenso: Human iPSC-derived Sensory Neurons 250](#_Toc73956031)

[14.71 Thermo Fisher Scientific, Inc. 251](#_Toc73956032)

[14.71.1 Products for Stem Cell Culture 251](#_Toc73956033)

[14.71.2 Products for Stem Cell Characterization 251](#_Toc73956034)

[14.71.3 Products for Stem Cell Engineering 251](#_Toc73956035)

[14.72 TreeFrog Therapeutics 252](#_Toc73956036)

[14.72.1 C-Stem Technology 252](#_Toc73956037)

[14.73 VistaGen Therapeutics, Inc. 253](#_Toc73956038)

[14.73.1 CardioSafe 3D 253](#_Toc73956039)

[14.74 Waisman Biomanufacturing 254](#_Toc73956040)

[14.74.1 GMP iPSCs 254](#_Toc73956041)

[14.75 xCell Science, Inc. 255](#_Toc73956042)

[14.75.1 Control Lines 255](#_Toc73956043)

[14.75.2 Products 255](#_Toc73956044)

[14.75.3 Services 255](#_Toc73956045)

[14.76 Yashraj Biotechnology, Ltd. 256](#_Toc73956046)

[14.76.1 Products and Services for Drug Discovery 256](#_Toc73956047)

**INDEX OF FIGURES**

[FIGURE 2.1: The Share of iPSC-related Research Compared with other Stem Cell Types 20](#_Toc37370896)

[FIGURE 2.2: Major Focuses of iPSC Companies 21](#_Toc37370897)

[FIGURE 2.3: Commercially Available iPSC-Derived Cell Types 22](#_Toc37370898)

[FIGURE 2.4: Relative Use of iPSC-Derived Cell Types in Toxicology/Safety Testing Assays 23](#_Toc37370899)

[FIGURE 2.5: Toxicology/Safety Testing Assays using iPSC-Derived Cell Types 24](#_Toc37370900)

[FIGURE 3.1: CiRA’s Budget of ¥6.37 Billion 29](#_Toc37370901)

[FIGURE 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2020 34](#_Toc37370902)

[FIGURE 4.2: Percent Share of Published Articles by Research Themes 35](#_Toc37370903)

[FIGURE 4.3: Percent Share of Published Articles by Disease Type 36](#_Toc37370904)

[FIGURE 4.4: Percent Share of iPSC Research Publications by Country 37](#_Toc37370905)

[FIGURE 5.1: Number of Patents Granted, Being Sought, and “Dead” 38](#_Toc37370906)

[FIGURE 5.2: Patent Families by Filing Jurisdiction 40](#_Toc37370907)

[FIGURE 5.3: Patent Families by Applicant Origin 41](#_Toc37370908)

[FIGURE 5.4: Top Ten Global Applicants 42](#_Toc37370909)

[FIGURE 5.5: Top Ten Global Collaborators on PSC/iPSC Patents 43](#_Toc37370910)

[FIGURE 5.6: Share of Patents on iPSC Preparation Technologies by Geography 44](#_Toc37370911)

[FIGURE 5.7: Percent Share of iPSC Preparation Methods in the U.S., Japan and Europe 45](#_Toc37370912)

[FIGURE 5.8: Percent Share of Patents Related to Cell Types Differentiated from iPSCs 46](#_Toc37370913)

[FIGURE 5.9: Percent Share of Patent Applications for Disease-Specific Cell Technologies 48](#_Toc37370914)

[FIGURE 5.10: Percent Share of Patents Representing Different Disorders 49](#_Toc37370915)

[FIGURE 6.1: Number of Clinical Trials Involving iPSCs by Year, 2006-2020 50](#_Toc37370916)

[FIGURE 6.2: Clinical Trials Involving iPSCs by Major Diseases 58](#_Toc37370917)

[FIGURE 6.3: Clinical Trials Involving iPSCs by Country 59](#_Toc37370918)

[FIGURE 7.1: Number of NIH Funding for iPSC Projects, 2010-2020 60](#_Toc37370919)

[FIGURE 7.2: Value of NIH Funding for iPSCs by Year, 2010-2020 61](#_Toc37370920)

[FIGURE 8.1: Overview of iPSC Technology 69](#_Toc37370921)

[FIGURE 8.2: Generation of iPSCs from MEF Cultures through 24 Factors by Yamanaka 70](#_Toc37370922)

[FIGURE 8.3: The Roles of OSKM Factors in the Induction of iPSCs 71](#_Toc37370923)

[FIGURE 8.4: Schematic Representation of Delivery Methods for iPSCs Induction 74](#_Toc37370924)

[FIGURE 8.5: Overview of Four Key Methods of Gene Delivery 76](#_Toc37370925)

[FIGURE 9.1: Workflow in iPSC Banks 83](#_Toc37370926)

[FIGURE 10.1: Biomedical Applications of iPSCs 94](#_Toc37370927)

[FIGURE 10.2: Relative Use of iPSC-Derived Cell Types in Toxicity Testing 106](#_Toc37370928)

[FIGURE 10.3: A Schematic for iPSC-Based Disease Modeling 107](#_Toc37370929)

[FIGURE 10.4: Proportion of iPS Cell Lines Generated by Disease Type 114](#_Toc37370930)

[FIGURE 10.5: Proportion of iPSC Sources in Cardiac Studies 115](#_Toc37370931)

[FIGURE 10.6: Proportion of Vector Types used in Reprogramming 116](#_Toc37370932)

[FIGURE 10.7: The Proportion of Differentiated Cardiomyocyte Types 117](#_Toc37370933)

[FIGURE 10.8: Schematic for iPSC-Based Cell Therapy 126](#_Toc37370934)

[FIGURE 11.1: Schematic Representation of Printing Techniques used for iPSC Bioprinting 139](#_Toc37370935)

[FIGURE 11.2: Schematic Showing the use of iPSCs in Protecting Endangered Species 144](#_Toc37370936)

[FIGURE 11.3: Funding raised by Cultured Meat Companies, 2016-2019 146](#_Toc37370937)

[FIGURE 11.4: Estimated Global Market for Cultured Meat, 2023-2030 148](#_Toc37370938)

[FIGURE 13.1: Estimated Global Market for iPSCs by Geography through 2026 157](#_Toc37370939)

[FIGURE 13.2: Estimated Global Market for iPSCs by Technology through 2026 159](#_Toc37370940)

[FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application through 2026 162](#_Toc37370941)

[FIGURE 13.4: Estimated Global Market Share for Differentiated Cell Types, 2020 163](#_Toc37370942)

[FIGURE 14.1: Comparison of Conventional Meat Production and Cultured Meat Production 167](#_Toc37370943)

**INDEX OF TABLES**

[TABLE 2.1: Companies Offering Commercially Available iPSC Technologies 26](#_Toc73956102)

[TABLE 2.2: Advantages and Limitations of iPSC Technology 27](#_Toc73956103)

[TABLE 3.1: Timeline of the Most Important Milestones in iPSC Research, 2006-2019 28](#_Toc73956104)

[TABLE 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2021 33](#_Toc73956105)

[TABLE 5.1: Patent Families by Filing Jurisdiction 39](#_Toc73956106)

[TABLE 5.2: Patents Granted and Patents Pending in the Global Patent Landscape 49](#_Toc73956107)

[TABLE 6.1: Select Clinical Trials involving iPSCs as of May 2021 51](#_Toc73956108)

[TABLE 6.1: (CONTINUED) 52](#_Toc73956109)

[TABLE 6.1: (CONTINUED) 53](#_Toc73956110)

[TABLE 6.1: (CONTINUED) 54](#_Toc73956111)

[TABLE 6.1: (CONTINUED) 55](#_Toc73956112)

[TABLE 6.1: (CONTINUED) 56](#_Toc73956113)

[TABLE 6.1: (CONTINUED) 57](#_Toc73956114)

[TABLE 7.1: NIH Funding for iPSC Projects in 2020 62](#_Toc73956115)

[TABLE 7.1: (CONTINUED) 63](#_Toc73956116)

[TABLE 7.1: (CONTINUED) 64](#_Toc73956117)

[TABLE 7.1: NIH’s Intended Funding Through its Component Organizations in 2020 65](#_Toc73956118)

[TABLE 7.2: NIH Funding for Select Universities/Organizations for iPSC Studies 65](#_Toc73956119)

[TABLE 7.2: (CONTINUED) 66](#_Toc73956120)

[TABLE 7.3: CIRM Funding for Clinical Trials Involving iPSCs 67](#_Toc73956121)

[TABLE 7.3: (CONTINUED) 68](#_Toc73956122)

[TABLE 8.1: Characterization of iPSCs 70](#_Toc73956123)

[TABLE 8.2: Reprogramming Factors used in the Generation of iPSCs 72](#_Toc73956124)

[TABLE 8.3: Different Cell Sources and Different Combinations of Reprogramming Factors 73](#_Toc73956125)

[TABLE 8.1: Comparative Effectiveness of Different Vector Types 77](#_Toc73956126)

[TABLE 8.2: iPSC Disease Models using Isogenic Control Lines Generated by CRISPR/Cas9 78](#_Toc73956127)

[TABLE 8.2: (CONTINUED) 79](#_Toc73956128)

[TABLE 9.1: Cell Sources and Reprogramming Agents used in iPSCs Banks 82](#_Toc73956129)

[TABLE 9.2: Diseased iPSC Lines Available in CIRM Repository 84](#_Toc73956130)

[TABLE 9.3: CIRMS’ iPSC Initiative Awards 85](#_Toc73956131)

[TABLE 9.4: Research Grade iPSCs Available with RMP 86](#_Toc73956132)

[TABLE 9.5: Research Grade iPSC Lines for Orphan and Rare Diseases Available with RMP 87](#_Toc73956133)

[TABLE 9.6: SCTL’s Collaborations 88](#_Toc73956134)

[TABLE 9.7: A Partial List of iPSC Lines Available with EBiPC 89](#_Toc73956135)

[TABLE 9.8: List of Disease-Specific iPSCs Available with RIKEN 90](#_Toc73956136)

[TABLE 9.8: (CONTINUED) 91](#_Toc73956137)

[TABLE 9.8: (CONTINUED) 92](#_Toc73956138)

[TABLE 9.9: An Overview of iPSC Banks Worldwide 93](#_Toc73956139)

[TABLE 10.1: Providers of iPS Cell Lines and Parts Thereof for Research 97](#_Toc73956140)

[TABLE 10.2: Comparison of hiPSC-Based & Animal-Based Drug Discovery 98](#_Toc73956141)

[TABLE 10.3: Drug Discovery for Cardiovascular Diseases using iPSCs 99](#_Toc73956142)

[TABLE 10.3: (CONTINUED) 100](#_Toc73956143)

[TABLE 10.4: Drug Discovery for Neurological and Neuropsychiatric Diseases using iPSCs 101](#_Toc73956144)

[TABLE 10.4: (CONTINUED) 102](#_Toc73956145)

[TABLE 10.5: Drug Discovery for Rare Diseases using iPSCs 102](#_Toc73956146)

[TABLE 10.5: (CONTINUED) 103](#_Toc73956147)

[TABLE 10.6: Examples of Drug Testing in iPSC-Derived Disease Models 104](#_Toc73956148)

[TABLE 10.6: (CONTINUED) 105](#_Toc73956149)

[TABLE 10.7: Published Human iPSC Disease Models 108](#_Toc73956150)

[TABLE 10.7: (CONTINUED) 109](#_Toc73956151)

[TABLE 10.7: (CONTINUED) 110](#_Toc73956152)

[TABLE 10.7: (CONTINUED) 111](#_Toc73956153)

[TABLE 10.7: (CONTINUED) 112](#_Toc73956154)

[TABLE 10.8: Partial List of Cardiovascular and Related Diseases Modeled with iPSCs 113](#_Toc73956155)

[TABLE 10.9: iPSC-Derived Organoids for Modeling Development and Disease 118](#_Toc73956156)

[TABLE 10.10: Liver Diseases and Therapeutic Interventions Modeled using iPSCs 119](#_Toc73956157)

[TABLE 10.10: (CONTINUED) 120](#_Toc73956158)

[TABLE 10.11: Examples of iPSC-Based Neurodegenerative Disease Modeling 121](#_Toc73956159)

[TABLE 10.11: (CONTINUED) 122](#_Toc73956160)

[TABLE 10.11: (CONTINUED) 123](#_Toc73956161)

[TABLE 10.11: (CONTINUED) 124](#_Toc73956162)

[TABLE 10.12: Cancer-Derived iPSCs 125](#_Toc73956163)

[TABLE 10.13: iPSC-Derived Cell Thearpeutics Being Tested within Clinical Trials Worldwide 127](#_Toc73956164)

[TABLE 10.13: (CONTINUED) 128](#_Toc73956165)

[TABLE 10.13: (CONTINUED) 129](#_Toc73956166)

[TABLE 10.14: U.S. Clinical Trials Involving iPSCs 135](#_Toc73956167)

[TABLE 10.14: (CONTINUED) 136](#_Toc73956168)

[TABLE 11.1: Features of Different Bioprinting Techniques 140](#_Toc73956169)

[TABLE 11.2: Bioprinting of iPSC-Derived Tissues 141](#_Toc73956170)

[TABLE 11.3: Timeline of Achievements Made using iPSCs for Conservation of Animals 143](#_Toc73956171)

[TABLE 11.4: Companies Working on Meat Production based on Cellular Agriculture 145](#_Toc73956172)

[TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2020-2027 157](#_Toc73956173)

[TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2020-2027 159](#_Toc73956174)

[TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2020-2027 161](#_Toc73956175)

[TABLE 13.4: Estimated Global Market for iPSCs by Differentiated Cell Types, 2020-2027 163](#_Toc73956176)

**About BioInformant**

BioInformant is the first and only market research firm to specialize in the stem cell industry.

BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, Goldman Sachs, and GE Healthcare, BioInformant is your global leader in stem cell industry data.